Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events
pharmaceutical investing Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo
Amarin Reports Record Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Operations
cannabis investing University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria’s TurboCBDTM.
pharmaceutical investing Protext Mobility Discusses Potential for Phytofare to treat Type II Diabetes
New Clinical and Pre-Clinical Data Presented at American College of Cardiology Meeting on the Effect of EPA Therapy in Statin-Treated Patients and on Endothelial Function in Exploratory Studies
Prismo Metals Announces Closing of Upsized Private Placement Silver King Exploration to Begin in July
